Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies to join Lung Cancer Initiative of North Carolina event on November 5

Neutral Impact 1 of 5 other Written later

bioAffinity Technologies announced in a press release that it will take part in the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026, to highlight its CyPath Lung test during National Lung Cancer Awareness Month. The filing contains no financial results, guidance, or transaction details, so it offers shareholders no new financial information.

Key points

  • Event: Lung Cancer Initiative of North Carolina's Battle of the Blues, November 5, 2026
  • Company product featured: CyPath Lung, a noninvasive lung cancer detection test marketed as a Laboratory Developed Test
  • The 8-K contains no financial figures, guidance, or transaction terms

The filing

CompanybioAffinity Technologies, Inc. (BIAF)
Form8-K, current report
Filed with the SECOct 29, 2026, 8:30 AM ET
Accession number0001493152-26-049188

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.